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Centipede venoms as a source of drug leads 
 
ABSTRACT 
Introduction: Centipedes are one of the oldest and most successful lineages of venomous terrestrial 
predators. Despite their use for centuries in traditional medicine, centipede venoms remain poorly 
studied. However, recent work indicates that centipede venoms are highly complex chemical arsenals 
that are rich in disulfide-constrained peptides that have novel pharmacology and three-dimensional 
structure. 
 
Areas covered: This review summarizes what is currently know about centipede venom proteins, with 
a focus on disulfide-rich peptides that have novel or unexpected pharmacology that might be useful 
from a therapeutic perspective. We also highlight the remarkable diversity of constrained three-
dimensional peptide scaffolds present in these venoms that might be useful for bioengineering of drug 
leads. 
 
Expert opinion: The resurgence of interest in peptide drugs has stimulated interest in venoms as a 
source of highly stable, disulfide-constrained peptides with potential as therapeutics. Well-studied 
venomous taxa such as cone snails and snakes have yielded FDA-approved drugs, while ancient 
invertebrate predators such as spiders and sea anemones have yielded molecules that are currently in 
preclinical studies and clinical trials, respectively. However, until recently, the paucity of research on 
centipede venoms made it easy to discount them as a potential source of peptides with therapeutically 
useful properties. Seminal studies over the past five years have revealed that centipede venoms have 
exceedingly complex proteomes that are perhaps richer than any other venom in unique disulfide-rich 
peptide scaffolds. Like most arthropod predators, centipede venoms are rich in peptides that target 
neuronal ion channels and receptors, but it is also becoming increasingly apparent that many of these 
peptides have novel or unexpected pharmacological properties with potential applications in drug 
discovery and development. 
 
KEYWORDS 
therapeutic; biologic; peptide drug; drug discovery; bioengineering; centipede venom; venom peptide; 
venomics; ion channel. 
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1. Introduction 
1.1 The current landscape of venom-derived drugs 
There are currently six FDA-approved venom-derived drugs that are used to treat a variety of 
disorders ranging from hypertension to pain and diabetes [1]. Many more venom-derived molecules 
that target an even wider range of disorders, including autoimmune disease, stroke and cancer, are in 
clinical and preclinical development [2-10]. Most of these molecules were derived from just a few 
well-studied venomous taxa [5,11], and therefore venoms remain an underutilized source of 
pharmacologically active compounds. For example, it has been estimated that less than 1% of the 
repertoire of bioactive spider-venom peptides has been sampled, despite spiders being regarded as one 
of the better studied venomous animals [12]. Venomous animals encompass a phyletic diversity that is 
hugely underappreciated, which has left entire groups of independently evolved venomous animals 
almost completely unstudied [13,14]. Centipedes are one such group. Despite their use for centuries in 
traditional medicine [15-17], centipede venoms remain poorly studied from a biochemical and 
pharmacological perspective, and consequently they are underappreciated as a potential source of drug 
leads. 
 
It has recently been shown that centipede venoms are a rich source of peptides with unusual structural 
and pharmacological diversity [16,18]. While peptides have emerged over the past decade as an 
attractive source of new therapeutics [19], naturally occurring peptides often suffer from intrinsic 
weaknesses such as poor stability and bioavailability that limit their potential as drugs [20]. In 
contrast, venom peptides often have remarkable chemical, thermal and biological stability due to their 
compact three-dimensional structures that are typically reinforced by numerous disulfide bonds 
[4,21,22]. Moreover, the intrinsic properties that allow venom peptides to exert their function—
namely potency, selectivity, stability, and solubility—are highly desirable traits for therapeutics. 
 
1.2. Centipedes: old and venomous 
With the possible exception of scorpions, centipedes (Class Chilopoda) are the oldest lineage of 
venomous terrestrial predators [23], with a fossil record dating back 420 million years. Not to be 
confused with their non-venomous sister-class, the millipedes (Class Diplopoda), centipedes are the 
main predatory group within Myriapoda. They are a highly successful group of venomous animals 
with approximately 3,500 extant species, making them more speciose than snakes and scorpions [5]. 
Extant centipedes are classified into five orders: Scutigeromorpha (house centipedes), Lithobiomorpha 
(stone centipedes), Geophilomorpha (earth centipedes), Scolopendromorpha (popular in the pet trade, 
often referred to as scolopenders, and includes giant species) and Craterostigmomorpha (Figure 1). 
With the exception of Craterostigmomorpha, which is represented by only two species occurring in 
New Zealand and Tasmania, these orders are distributed worldwide across all continents except 
Antarctica. 
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Centipedes are almost exclusively predators, and most species are nocturnal. Although they prey upon 
a wide diversity of invertebrates, with some larger species feeding on vertebrates, most centipede diets 
consist primarily of arthropods, which they incapacitate using venom injected through a pair of 
powerful pincer-like appendages called forcipules. Venom is expelled from the glands via a cuticular 
duct through a pore located near the tip on the outer curvature of the forcipules. Each gland is 
composed of a collection of distinct secretory units, each of which comprises 3–4 cells [24]. Recent 
mass spectrometry imaging studies have revealed that peptide toxins are produced in a heterogeneous 
fashion within the venom gland, with distinct zip codes for each peptide [25,26]. 
 
1.3. Centipede venoms are complex chemical arsenals 
Centipedes are notorious for delivering painful defensive bites [24]. However, despite their size and 
the frequency of encounters with humans, very little is known about centipede venom [18,24]. What 
we do know, however, suggests that centipedes are an excellent source of novel bioactive molecules. 
The great age of their lineage, the deep evolutionary divergences between living orders, and the large 
number of extant species, create a phylogenetic breath of independently evolving venoms that greatly 
exceeds that of most venomous taxa that have already yielded drugs, including reptiles, cone snails, 
and scorpions. Moreover, the majority of non-enzyme protein families described from centipede 
venom appear to be unique to centipedes, and consequently they are likely to include novel peptides 
and proteins with therapeutically useful biological functions [18]. 
 
The ancestral centipede venom contained a mix of high molecular weight proteins (HMWPs) and low 
molecular weight peptides, with further expansion of the venom cocktail in subsequent lineages [18]. 
The venom peptides, which are of most interest from a drug discovery perspective, are extraordinarily 
diverse [25,27-32]. Undheim et al. [30] classified centipede venom peptides into 31 phylogenetically 
distinct families of scutigerotoxins (SCUTX1–3) and scoloptoxins (SLPTX1–28). Remarkably, 24 of 
these families are comprised of cysteine-rich peptides with 1–6 putative disulfide bonds, the majority 
of which show no similarity to known peptides and do not contain any recognizable structural or 
functional domains. Thus, centipede venoms appear to be an excellent source of novel peptides. 
 
2. Novel disulfide-rich peptide scaffolds in centipede venom 
2.1 Centipede venoms are a rich source of novel structural scaffolds 
Among the properties that make venoms attractive as a potential source of therapeutics is the 
abundance of disulfide-rich peptides [5,33]. The internal cross-bracing provided by covalent disulfide 
bonds creates a rigid structural framework that provides resistance to chemical and thermal 
denaturation as well as degradation by proteases [4,21,22,34,35]. Although peptides of similar 
structure can harbor a diversity of interesting pharmacological properties, the characterization of new 
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disulfide frameworks is of particular interest from a drug discovery perspective as they are more likely 
to exhibit novel pharmacology [36] and expand the repertoire of structural templates for 
bioengineering purposes [37-41]. 
 
Centipede venoms appear to be a richer source of novel disulfide-rich peptide scaffolds than other 
venoms studied to date. There are 24 phylogenetically distinct disulfide-rich peptide scaffolds that are 
currently recognized in centipede venoms: SCUTX1–2, SLPTX1–20, SLPTX26, and SLPTX28 [18]. 
Remarkably, 19 of these bear no obvious resemblance to the sequence or cysteine framework of any 
known disulfide-rich peptide. Several of these peptide-toxin families show substantial variation in 
terms of length, primary structure, and cysteine-pattern [30]. For example, members of SLPTX11 
range in size from 4 to 20 kDa, and contain anywhere from 2 to 9 disulfide bonds. Consistent with this 
diversity of size and cysteine framework, the masses of centipede venom peptides do not follow a 
bimodal distribution (Figure 2) as has been observed for venom peptides from spiders and scorpions 
[42]. This is consistent with centipede venoms containing a much greater diversity of three-
dimensional peptide scaffolds than scorpions and spiders which are both dominated by a single 
peptide fold (i.e., cystine-stabilised α/β defensin fold [33] and inhibitor cystine knot fold [43,44], 
respectively). 
 
Despite the diversity of novel disulfide-rich peptide scaffolds present in centipede venoms, the Protein 
Data Bank (PDB) currently contains structures for only four centipede venom peptides. Moreover, 
these structures belong to just two toxin families, SLPTX3 and SLPTX4, and hence they provide a 
mere glimpse of the structural diversity present in centipede venoms. 
 
2.2 The SLPTX3 fold: weaponization of a hormone 
The first reported structure of a centipede venom peptide was that of µ-SLPTX3-Ssm6a (henceforth 
just Ssm6a), a three-disulfide, 46-residue peptide from the Chinese red-headed centipede Scolopendra 
subspinipes mutilans (Figure 3a,b) [35]. The all-helical 3D structure of Ssm6a revealed that it is 
derived from a family of ubiquitous ecdysozoan peptide hormones known as the ion transport 
peptide/crustacean hyperglycemic hormone (ITP/CHH) family [35]. The 3D structure of ITP/CHH 
peptides is comprised of five helices (α1 to α5), of which three are inter-connected by disulfide bonds 
(α1–α3, α2–α3, and α2–α4) [45]. However, in weaponized ITP/CHH peptides—that is, ITP/CHH 
peptides that are found in venoms and exert a toxic role—the fifth helix has been removed to create 
helical arthropod-neuropeptide-derived (HAND) toxins [35] (Figure 3b–d). This derivation, which rids 
HAND toxins of the only helix not stabilized by disulfide bonds, appears to provide these peptides 
with greatly increased stability compared to the ancestral hormone, and consequently this helix 
ablation was likely a key innovation during weaponization of the hormone [35].  
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Remarkably, HAND toxins have arisen on at least two separate occasions within the last 150 million 
years—once in spiders of the genus Eratigena (previously Tegenaria) and once in the centipede genus 
Scolopendra. However, centipede HAND toxins have undergone greater radiation than those in 
spiders, with the HAND-form accounting for the vast majority of molecular diversity in the SLPTX3 
family [29-31]. In centipede HAND toxins, one turn of α3 was excised to remove the residues between 
cysteines 4 and 5, thereby creating a highly compact and ultrastable peptide fold [21,35]. For example, 
no degradation of Ssm6a was observed when the peptide was incubated for one week in human 
plasma in vitro, and the peptide was shown to be highly resistant to thermal denaturation in 4 M urea; 
remarkably, the midpoint of the thermal unfolding transition (Tm) was even very high (71˚C) in 8 M 
urea [21]. Hence, the HAND peptide scaffold appears to be an ideal structural template for 
engineering therapeutically useful biological functions, as has been done successfully with inhibitor 
cystine knot toxins [40,41]. 
 
2.3 The SLPTX4 fold: Rho-toxin 
Rho-toxin (RhTx) is a 27-residue peptide (Figure 4a) isolated from the venom of S. subspinipes 
mutilans [46]. It contains four cysteines with a pattern typical of the SLPTX4 family. RhTx folds into 
a relatively compact structure held together by two disulfide bridges (C1–C3, C2–C4) that anchors a 
highly disordered N-terminal tail to the structured C-terminal half of the peptide (Figure 4b). All 
charged residues are restricted to this C-terminal ordered region, and they are located on the same face 
of the folded toxin.  
 
It is interesting to note the marked differences between the three-dimensional scaffolds of the SLPTX3 
and SLPTX4 peptide families despite their superficially similar neurotoxic functions. The SPLTX3 
fold is comprised entirely of α helices (Figure 3b–d) while the SPLTX4 fold is largely devoid of 
regular secondary structure (Figure 4b). Moreover, whereas the SPLTX3 fold is compact and rigid, the 
SLPTX4 fold as exemplified by RhTx is less compact and, at least in the N-terminal region, 
structurally dynamic. Considering the immense structural diversity underlying the pharmacological 
activities exhibited by centipede venom peptides, it is apparent that centipede venoms are not only a 
promising source of natural bioactive peptides but also a rich toolbox for bioengineering of 
therapeutic leads. 
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3. Novel pharmacological activities in centipede venom peptides 
The venoms of spiders and scorpions are rich in peptide neurotoxins that target the insect 
neuromuscular junction and central nervous system. These peptide neurotoxins primarily target 
presynaptic ion channels involved in electrical signaling and neurotransmitter release, including 
voltage-gated sodium (NaV), calcium (CaV) and potassium (KV) channels [47-56]. As for arachnids, 
centipede venoms also appear to be rich in peptide neurotoxins that target voltage-gated ion channels: 
for example, numerous centipede-venom peptides have been isolated that inhibit NaV, CaV, and KV 
channels in rat dorsal root ganglion sensory neurons [28,29,57]. Small, non-reticulated peptides with 
antimicrobial activity have also been isolated from centipede venoms [58,59]. While some of these 
peptides may be interesting from a drug discovery perspective, similar pharmacological activities have 
been noted previously for venom peptides from a wide variety of venomous taxa. Thus, in the 
following sections we focus on novel pharmacological activities that have so far been reported only 
for centipede venoms, or activities that one might not expect to find in centipede venoms. In Table 1 
we summarize the complete range of pharmacological activities that have been reported for centipede 
venom peptides. 
 
3.1 Sneaking up on a target: SSD609 inhibits KCNQ1 via interaction with the auxiliary subunit 
Venom peptides that modulate the activity of voltage-gated ion channels typically interact with either: 
(i) the pore region of the channel, acting much like a cork in a bottle to impede ion flow; or (ii) the 
voltage-sensor domain in order to alter the voltage-dependence of channel activation or inactivation 
(so-called gating modifiers). In contrast, the centipede-venom peptide SS609 indirectly inhibits the 
voltage-gated potassium channel KCNQ1 (KV7.1) by interacting with its auxiliary subunit [60]. 
 
SSD609 is a 47-residue peptide first purified from venom of Scolopendra subspinipes dehaani [29]. It 
is a member of the SPLTX3 family of toxins and is closely related to Ssm6a; its name based on the 
rational nomenclature proposed for centipede-venom peptides is κ-SLPTX3-Sd1a. Like Ssm6a, it has a 
HAND-toxin fold, with four α helices connected by three disulfide bonds (Figure 3c). As might be 
expected based on the high level of sequence identity between Ssm6a and SSD609 (78%; Figure 3a), 
their 3D structures are very similar and can be superimposed with a backbone RMSD of 1.4 Å 
(compare Figures 3b and 3c). SSD609 inhibits slow-activating IKs currents mediated by KCNQ1 in 
guinea pig cardiac myocytes with IC50 ~210 nM, as well as currents from KCNQ1 heterologously 
expressed in CHO cells with an IC50 of ~650 nM, but only in the presence of the KCNE1 or KCNE3 
auxiliary subunit [60]. This makes SSD609 significantly more potent than MT2-2, an engineered 
scorpion toxin that inhibits KCNQ1/KCNE1 with IC50 ~1.5 µM via a classical pore blocking 
mechanism [61]. Moreover, SSD609 is highly selective for KCNE1 and KCNE3 over the closely 
related KCNE2 and KCNE4 auxiliary subunits. Based on mutational analysis of KCNE1 it was 
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proposed that SSD609 binds to an amphipathic helix near the N-terminus of KCNE1 located on the 
extracellular surface of the membrane [60].  
 
The mechanism by which interaction of SSD609 with KCNE1/KCNE3 inhibits ion flow through the 
associated KCNQ1 channel remains to be determined, but it has potential therapeutic importance 
because KCNQ1 is generally associated with KCNE1 or KCNE3 in vivo and KCNE1 can also interact 
with the critical cardiac channel hERG (KV11.1) [62]. For example, SSD609 might provide a useful 
template for development of novel KCNQ1 inhibitors for use in patients with gain-of-function 
mutations in KCNQ1 leading to Short QT Syndrome or familial atrial fibrillation [63], especially since 
the specific association of such inhibitors with the auxiliary subunit is likely to limit the chance of 
undesirable off-target effects on other KV channels. A significantly bigger clinical problem is loss-of-
function mutations in KCNE1 and KCNQ1 leading to Long QT Syndrome [63], and hence it will be 
interesting in future research to examine whether SSD609 can be engineered to agonize rather than 
inhibit KCNQ1, although in this case on-target toxicity might be difficult to avoid. 
 
3.2 Turning up the heat on TRPV1: RhTx agonizes TRPV1 by lowering the heat activation threshold 
Like other venomous arthropods, centipedes use their venom for defense as well as prey capture. One 
of the most effective methods to deter predators is to activate receptors in pain-sensing neurons 
(nociceptors) in order to induce pain. For example, venom peptides have been discovered that induce 
pain by activating components of the pain signaling machinery in sensory neurons, including the 
transient receptor potential channel TRPV1 [36,64], acid-sensing ion channels [65], and the voltage-
gated sodium channel NaV1.1 [66]. While agonists of the pain signaling machinery may not be useful 
therapeutically, they can reveal new analgesic targets. For example, a spider-venom peptide that 
potently and selectively agonizes NaV1.1 was used to reveal an unexpected role for this channel in 
signaling mechanical pain [66]. 
 
It was recently shown that the centipede-venom peptide RhTx induces pain by agonizing TRPV1 [46], 
a nonselective cation channel that is responsible for sensing noxious heat in sensory neurons [36]. 
RhTx activates TRPV1 with only moderate potency (EC50 ~520 nM) but it is highly selective, with no 
effect on homologous TRPV2, TRPV3 or TRPV4 channels or on voltage-gated NaV, CaV or KV 
channels. Mutagenesis studies indicate that the toxin wedges into the extracellular crevice between 
neighboring subunits of the tetrameric TRPV1 channel, making contacts with both the turret and pore 
helix [46]. At 100 nM concentration, RhTx lowers the threshold temperature for activation of TRPV1 
by 6˚C, thereby causing the nociceptive pathway that normally responds to noxious heat to be 
activated at body temperatures. Interestingly, the mechanism of action of RhTx is distinctly different 
to that of capsaicin, the prototypic TRPV1 agonist found in chili peppers. The agonistic action of 
RhTX requires a transition of the heat activation pathway as it is inactive at temperatures below the 
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threshold for activation of TRPV1, whereas this is not the case for capsaicin. It has been suggested 
that this may allow centipedes to inflict pain in predators such as birds and snakes that are insensitive 
to capsaicin [46]. 
 
Centipedes are notorious for inducing extreme pain in envenomated humans [24], and the rapid 
binding kinetics of RhTx [46] is consistent with the rapid onset of pain after a centipede bite. 
However, it will be interesting in future studies to determine whether there are centipede toxins that 
engage other components of the pain signaling machinery in addition to TRPV1. 
 
3.3 ω-SLPTX-Ssm1a: a unique CaV channel agonist 
While humans express ten different CaV channel isoforms (CaV1.1–1.4, CaV2.1–2.3, and CaV3.1–3.3), 
insects have a much more limited repertoire, with most expressing only a single isoform of each major 
subtype (CaV1, CaV2, and CaV3) [50,51]. Insect CaV1 and CaV2 channels are essential, as knockout of 
either one in Drosophila melanogaster is embryonic lethal [50]. Hence, insects are highly sensitive to 
modulation of the activity of these channels and therefore it is not surprising that many venoms are 
rich in CaV channel inhibitors. Indeed, the defining pharmacology for vertebrate CaV2.1 and CaV2.2 
channels is susceptibility to inhibition by the venom peptides ω-agatoxin IVA and ω-conotoxin GVIA 
from spiders and cone snails, respectively [51].  
 
While CaV channel inhibitors are common in venoms, CaV channel agonists are exceedingly rare; the 
only known example is glycerotoxin, a large 320-kDa neurotoxic protein from venom of the glycerid 
polychaete worm Glycera tridactyla that selectively activates CaV2.2 [67]. Moreover, only a few 
synthetic compounds have been developed that activate CaV channels, and most of these selectively 
agonize CaV1 subtypes [68,69]. Thus, the ability of the centipede venom toxin ω-SPLTX-Ssm1a 
(hereafter Ssm1a) to activate CaV channel currents in rat dorsal root ganglion neurons (which contain 
predominantly CaV2 and CaV3 subtypes) is unique for a venom peptide [28]. While potency remains to 
be fully quantified, 1 µM peptide was sufficient to increase CaV channel currents by ~70%. Ssm1a is 
an 83-residue SLPTX5-family peptide isolated from the venom of S. subspinipes mutilans. It is 
unusual both for its relatively large size (8.8 kDa) and for containing seven cysteine residues. Free 
cysteines are generally not found in venom peptides, so the uneven number of cysteines might indicate 
that Ssm1a forms disulfide-linked homodimers as do several venom peptides from snakes and cone 
snails [70-73]. There remains much to be learnt about Ssm1a, including its 3D structure and 
mechanism of action [28]. Currently there are no homologs of Sm1a in protein/DNA sequence 
databases, so its structure is likely to be novel. 
 
There are a number of diseases where CaV channel agonists might be therapeutically useful. For 
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example, the roscovitine derivative GV-58, a use-dependent CaV2.1 agonist, is being developed for 
treatment of Lambert-Eaton myasthenic syndrome in which progressive muscle weakness accrues due 
to autoantibody-mediated removal of presynaptic calcium channels at neuromuscular junctions 
[69,74]. Interestingly, the CaV1 agonists Bay K8644 and FPL 64176 both protect against 
neuromuscular dysfunction in a zebrafish model of amyotrophic lateral sclerosis, whereas roscovitine 
is ineffective, consistent with a greater role for CaV1 channels in stimulating neurotransmitter release 
at neuromuscular junctions in lower vertebrates [75]. Bay K8644 also protects against neuronal injury 
in a mouse model of ischemic stroke when delivered 12–24 h after reperfusion [76]. This seems 
counterintuitive given the critical role of intracellular calcium overload in the early stages of neuronal 
toxicity following ischemia [77], but is consistent with a specific role for CaV1 channels during 
recovery from ischemic injury [76]. Whether Ssm1a might be a useful lead compound for developing 
treatments for any of these disorders will depend on further investigations into its potency, stability, 
CaV subtype selectivity, and mode of action. 
 
3.4 Turning down the gain on pain: selective inhibition of NaV1.7 by Ssm6a 
NaV channels are widely distributed in the animal kingdom where they are responsible for initiation 
and propagation of action potentials in excitable cells. Insects express only a single NaV channel 
subtype, and consequently they are exquisitely sensitive to modulation of its activity. As a result, NaV 
channels are the most common target of chemical insecticides and they are disproportionately 
represented in the venoms of arthropod predators [51,53,78-80]. In contrast with insects, humans 
express nine different NaV channel subtypes (NaV1.1–NaV1.9), many of which are important 
therapeutic targets. The human subtypes often have distinctly different tissue distribution and 
physiological roles compared with insect NaV channels, and consequently venom peptides that evolved 
to paralyse/kill prey by targeting insect NaV channels can have therapeutic effects in mammals. For 
example, Amgen [81], AstraZeneca/MedImmune [82], Johnson & Johnson/Janssen [83], and Merck 
[84,85] have all examined the analgesic potential of spider-venom peptides that target the human 
NaV1.7 (hNaV1.7) channel. 
 
There is immense interest in hNaV1.7 as an analgesic target since humans with loss-of-function 
mutations in this channel have a congenital insensitivity to pain [86], whereas other sensory modalities 
with the exception of olfaction are unaffected [87]. Unfortunately, it has proved difficult to develop 
molecules that selectively inhibit hNaV1.7 without affecting key off-target subtypes such as hNaV1.4, 
hNaV1.5, and hNaV1.6 which are found in muscle, heart and myelinated motor neurons, respectively. 
However, the centipede venom peptide Ssm6a was shown to inhibit hNaV1.7 with high potency (IC50 
~ 25 nM) with 32-fold selectivity over hNaV1.2 and 150-fold selectivity over all other hNaV subtypes 
[21]. Ssm6a inhibits hNaV1.7 by inducing a depolarizing shift in the voltage-dependence of channel 
activation, without affecting steady-state inactivation, which is a characteristic feature of gating 
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modifier peptide toxins that interact with one or more of the voltage-sensor domains in voltage-gated 
ion channels [88]. Consistent with its potent and selective inhibition of hNaV1.7, Ssm6a proved to be 
at least as potent as morphine in rodent models of chemical, thermal, and acid-induced pain, and it did 
not cause any side-effects [21].  
 
While inhibition of hNaV1.7 is not a novel pharmacology for venom peptides, Ssm6a is much more 
selective than NaV channel toxins isolated from other venomous animals [53,89,90]. For reasons that 
remain unclear, it has proved difficult to recapitulate the activity of native SSm6a with recombinant or 
synthetic material [81]. It is possible that native Ssm6a contains a cryptic post-translational 
modification, such as L-to-D isomerization of one or more residues as has been noted in venom 
peptides from cone snails [91], platypus [92], and spiders [93]. Regardless of its pharmacological 
activity, recombinant Ssm6a has an unusual 3D fold with extraordinary thermal and biological 
stability (see Section 2.2), and therefore it might serve as a convenient disulfide-stabilized scaffold for 
engineering peptides with desired therapeutic function. 
 
3.5 Expect the unexpected: centipede-venom compounds with anti-thrombotic and fibrinolytic 
properties 
Most snake venoms are hemotoxic and therefore it is not surprising that they are a rich source of 
proteins and peptides that modulate the cardiovascular system of vertebrates [7]. Indeed, most of the 
venom-derived drugs in current use target the cardiovascular system and originated from snakes; these 
include compounds with antihypertensive, antiplatelet, and pro- and anticoagulation activity [5]. In 
contrast with snakes, centipede venoms are neurotoxic and they generally do not prey on vertebrates. 
The isolation of centipede-venom peptides with anti-thrombotic properties was therefore 
unanticipated. A pentapeptide (TNGYT) that weakly inhibits Factor Xa (IC50 ~ 74 mM) was purified 
from the venom of S. subspinipes mutilans [94]. However, while TNGYT prolongs whole blood 
clotting time and bleeding time in mice, its potency is well below the range that would make it a 
useful therapeutic lead. The venom of this centipede also contains a serine protease with fibrinolytic 
activity [95]. 
 
Although venom is likely to be the primary source of bioactive centipede peptides, whole-centipede 
extracts have been used in traditional medicine for centuries and other body tissues may yield 
interesting peptides. For example, a tripeptide (SQL) with antiplatelet activity was isolated from 
whole-body extracts of S. subspinipes mutilans [17,96]. It has been suggested that SQL might be a 
useful antithrombotic agent as it inhibits platelet aggregation in vitro and attenuates thrombus 
formation in vivo, without significant prolongation of bleeding time [17]. The isolation of three 
vertebrate-active cardiovascular modulators from venom and whole-body extract of a single centipede 
species suggests that centipedes might be a richer source of cardiovascular drug leads than would have 
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been anticipated based on their ecology and the limited number of investigations of their venom 
composition. 
 
4. Conclusions 
Despite their evolutionary success and wide geographic distribution, there are fewer than 25 literature 
reports on the molecular composition of centipede venoms, and these investigations cover a very 
limited range of the taxonomic diversity of these ancient venomous predators. Nevertheless, these 
pioneering studies have uncovered a wealth of unique peptide scaffolds in centipede venoms as well as 
novel and unexpected pharmacological activities. The next decade promises to herald a new era where 
fundamental studies of centipede venom are leveraged for drug discovery applications. 
 
5. EXPERT OPINION 
Biochemical and pharmacological investigations of centipede venom have lagged well behind studies 
of other venomous arthropods such as spiders and scorpions. Complete venom-peptide sequences are 
available for only seven species from four genera, which represents less than 0.25% of the taxonomic 
diversity of centipedes, and pharmacological data are available for an even smaller number of species. 
Remarkably, despite this taxonomic bias, the small number of studies undertaken to date have 
revealed that centipede venoms contain a remarkable diversity of disulfide-rich peptides that 
encompass a greater variety of constrained peptide scaffolds than present in any other venom [27-30]. 
Moreover, the sparse pharmacological sampling that has been performed to data indicates that the 
centipede venom arsenal includes peptides with novel and sometimes quite unexpected pharmacology. 
 
Centipedes are ancient animals with an independently evolved venom system that is very different to 
that of other terrestrial venomous predators such as arachnids and assassin bugs. Their trophic strategy 
relies entirely on venom for predation as they are not armored, they do not have physical apparatus 
such as the grasping pedipalps (claws) of scorpions for subduing prey, nor do they have alternative 
means of prey capture such as the silk used by spiders. Hence, one might have expected their venom 
to be replete with fast-acting neurotoxins and that has indeed turned out to be the case. What was 
unanticipated, but perhaps should not have been given their unique venom apparatus and long 
evolutionary history, is that the composition of centipede venoms is vastly different to that of all other 
venomous animals. Only seven studies to date have probed the centipede venom proteome in detail 
[25,27-32], yet these limited investigations have uncovered 19 novel disulfide-constrained peptide 
families. Given the very limited taxonomic sampling of centipede venoms to date, this is likely to be 
the tip of the iceberg and the next decade promises to reveal more novel centipede venom peptides as 
additional species are examined. 
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Detailed investigation of centipede venoms only became a reality this century when advances in 
proteomics and transcriptomics allowed the study of small venomous animals that secrete tiny 
amounts of venom [12]; the first detailed proteomic study of centipede venom was published in 2007 
[27] and the first combined proteomic/transcriptomic study in 2012 [29]. Investigations of centipede 
venoms are therefore still largely at the exploratory stage, with very few studies focused on drug 
discovery. Although promising lead compounds have been discovered [21], to our knowledge no 
centipede-venom compounds have reached clinical trials or even advanced preclinical studies. It was 
almost three decades before initial investigations of the molecular composition of snake venom in the 
1950s led to the blockbuster antihypertensive drug captopril in 1981 [97], and 20 years before the cone 
snail venom-peptide ω-conotoxin MVIIA, discovered during pioneering studies in Baldomero 
Olivera's lab in 1985 [98], became an FDA-approved analgesic in 2004 [99]. Thus, the next decade 
promises to be an exciting period where fundamental studies of centipede venom begin to be 
translated into therapeutic applications. Moreover, it will be particularly interesting to see whether 
some of the unique disulfide-constrained peptide scaffolds present in centipede venoms, such as the 
HAND toxin fold [35,60], prove as useful as the ubiquitous inhibitor cystine knot fold for engineering 
desirable therapeutic and diagnostic functions [40,41,100]. 
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ARTICLE HIGHLIGHTS 
• Centipedes are one of the oldest and most successful lineages of venomous predators but studies 
of their venom have been restricted to only a handful of the 3500 extant species. Despite recent 
advances in understanding the molecular composition of centipede venoms, they remain 
underappreciated as a potential source of therapeutics despite their use in traditional medicine for 
many centuries. 
• The venom apparatus of centipedes that is markedly different to that of other venomous 
arthropods such as spiders and scorpions. Moreover, in comparison to arachnids, centipede 
venoms contain a higher proportion of protein toxins and a more structurally diverse repertoire of 
peptide toxins. 
• Centipede venoms contain an astonishing variety of peptide toxins that encompass a greater 
diversity of disulfide-constrained peptide scaffolds than reported in any other venom. Studies to 
date have already identified 19 families of disulfide-rich peptides that appear to be unique to 
centipede venom. 
• Despite the immense diversity of putatively unique three-dimensional peptide folds in centipede 
venom, structures are currently available for only two of the 19 novel peptide-toxin families. 
Future exploration of these novel venom peptides is likely to expand the repertoire of disulfide-
stabilized structural templates suitable for bioengineering of drug leads and diagnostics. 
• Centipede venoms are rich in peptide toxins that inhibit presynaptic voltage-gated ion channels, as 
might be expected for a neurotoxic venom. However, these venoms also contain peptides with 
unexpected pharmacology, such as auxiliary subunit-mediated inhibition of KV7.1, activation of 
CaV channels, and even peptides with anti-thrombotic properties. 
• No centipede venom peptides have yet progressed to late-stage preclinical studies or clinical trials. 
However, the next decade promises to be a transformative period where fundamental 
investigations of centipede venom begin to be leveraged for drug discovery applications. 
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Figure legends 
 
Figure 1. Phylogeny of extant centipede orders. Consensus phylogeny for the five extant orders of 
Chilopoda. Photographed species are Scutigera coleoptrata (Scutigeromorpha), Craterostigmus 
tasmanianus (Craterostigmomorpha), Lithobius forficatus (Lithobiomorpha), Scolopendra sp. 
(Scolopendromorpha), Mecistocephalus sp. (Geophilomorpha). 
 
Figure 2. Mass distribution of centipede venom peptides. Histogram showing binned size 
distributions for predicted and observed centipede venom peptides (which we define as proteins 
smaller than 10 kDa) reported in the literature (total = 544). The inset shows the relative proportions 
of peptides and proteins (mass >10 kDa) in centipede venoms. 
 
Figure 3: The SLPTX3 fold. (a) Sequence alignment of SLPTX3 family members µ-SLPTX-Ssm6a 
(Ssm6a), κ-SLPTX3-Sd1a (SSD609), and κ-SLPTX-Ssm1a (Ssm1a). Conserved cysteine residues are 
highlighted in orange. Disulfide bonds are shown above the sequence alignment and the helices 
connected by each disulfide are indicated. Numbers at far right are backbone root mean squared 
deviation (rmsd) values for optimal pairwise superposition of the structures. The conserved all-helical 
secondary structure is shown below the sequence alignment. (b–d) Richardson representation of the 
3D structures of (b) Ssm6a (PDB 2MUN), (c) SSD609 (PDB 2MVT), and (d) Ssm1a (PDB 2M35). 
The four conserved helices are labeled in panel (c) and colored identically in each structure to 
highlight the high level of structural homology. Disulfide bonds are orange. 
 
Figure 4: The SLPTX4 fold. (a) Primary structure of RhTx. Cysteine residues are highlighted in red, 
while the lines above the sequence indicate disulfide connectivities. (b) Stereoview of the ensemble of 
10 RhTX structures (PDB 2MVA). The disulfide bonds (shown in red) connect the structured C-
terminal region to a highly disordered N-terminal region. 
  
	   22 
Figure 1 
 
 
 
  
	   23 
Figure 2 
 
 
 
  
	   24 
Figure 3 
 
 
 
  
	   25 
Figure 4 
 
 
 	  
T
able 1: Pharm
acological activities reported for centipede venom
 peptides. 
1B
ased on the rational nom
enclature described in {U
ndheim
, 2014 #10}; 2TTX
-S = tetrodotoxin-sensitive; 3N
D
 = not determ
ined; *N
o m
atch to sequence in any of the published 
venom
 gland or w
hole body transcriptom
es from
 this species; #Fragm
ent of peptide belonging to cysteine-rich peptide fam
ily SLPTX
15. 
Recom
m
ended(
nam
e
1(
Com
m
on(
toxin(nam
e(
SPLTX(
fam
ily(
Sequence(
accession(
PDB(
accession(
N
o.(of((
residues(
Cysteine(pattern(
Target(
(IC
50 (if(know
n)(
N
otes(
References(
μ"SLPTX
3 "Ssm
1a-
μ"SLPTX"Ssm
1a-
3-
P0DM
D2-
(U
niProt)-
—
-
32-
C–C–C–C-
TTX"S
2-N
a
V -
(9-nM
)-
Inhibitor;-also-insecticidal.-C"term
inally-truncated-version-
of-HAN
D-toxin-fold.--
{Yang,-2012-#30}-
μ"SLPTX
3 "Ssm
6a-
μ"SLPTX"Ssm
6a-
3-
P0DL36-
(U
niProt)-
2M
U
N
-
46-
C–C–C–CC–C-
hN
a
V 1.7-
(25-nM
)-
G
ating-m
odifier.-HAN
D-toxin-fold.-N
o-significant-effect-on-
other-hN
a
V -subtypes-except-hN
a
V 1.2-(IC
50 -~-813-nM
).--
{Yang,-2013-#7}-
κ"SLPTX
3 "Ssm
1a-
κ"SLPTX"Ssm
1a-
3-
I6RU
32-
(U
niProt)-
2M
35-
51-
C–C–C–CC–C-
K
V -
(44-nM
)-
HAN
D-toxin-fold.-Inhibitor.-
{Yang,-2013-#7}-
κ"SLPTX
4 "Ssm
1a-
Ssm
Tx"I-
4-
N
ot-available-
—
-
36-
C–C–C–C-
K
V 2.1-
(42-nM
)-
Pore-blocking-inhibitor.-M
inim
al-effect-on-K
V 1.1,-K
V 1.3–
1.4,-K
V 2.2,-K
V 3.1,-K
V 4.1–4.3-&
-N
a
V -channels.-
{Chen,-2014-#26}-
κ"SLPTX
7 "Ssm
2a-
κ"SLPTX"Ssm
2a-
7-
I6RA66-
(U
niProt)-
—
-
31-
C–C–C–C–CC-
K
V -
(570-nM
)-
Inhibits-K
V -currents-in-rat-DRG
-neurons.-
{Yang,-2013-#7}-
κ"SLPTX
11 "Ssm
3a-
κ"SLPTX"Ssm
3a-
11-
I6S7G
5-
(U
niProt)-
—
-
68-
C–C–C–C-
K
V -
(>200-nM
)-
W
eak-inhibitor-of-K
V -currents-in-DRG
-neurons.-
25%
-inhibition-at-200-nM
.-
{Yang,-2013-#7}-
κ"SLPTX
15 "Sd1a-
SSD559-
15-
KC144556-
(N
CBI)-
—
-
N
D
3-
8.56-kDa-
C–CXXXC–CXC–C-
K
V -
(~10-nM
)-
Inhibits-K
V -currents-in-rat-DRG
-neurons.-
{Liu,-2012-#11}-
ω
"SLPTX
5 "Ssm
1a-
ω
"SLPTX"Ssm
1a-
5-
I6R1R5-
(U
niProt)-
—
-
83-
C–C–C–C–C–C–C-
Ca
V-
Activator.-Increases-Ca
V -currents-in-DRG
-neurons-by-70%
-
at-1-µM
-and-120%
-at-10-µM
.-
and-120%
-at-5-µM
-
{Yang,-2012-#30}-
ω
"SLPTX
13 "Ssm
2a-
ω
"SLPTX"Ssm
2a-
13-
I6S390-
(U
niProt)-
—
-
54-
C–C–CC–C–C–C–C-
Ca
V -
(1590-nM
)-
Inhibits-Ca
V -current-in-DRG
-neurons-by-45%
--
at-500-nM
-
and-80%
-at-2.5-µM
-
{Yang,-2012-#30}-
ω
"SLPTX
15 "Sd1a-
SSD1052-
15-
KC145039-
(N
CBI)-
—
-
N
D
3-
6.03-kDa-
CXXXC–CXC-
Ca
V-
W
eak-inhibitor-of-Ca
V -current-in-DRG
-neurons.-8.6%
-
inhibition-at-10-nM
.-
{Liu,-2012-#11}-
κ-"SLPTX
3 "Sd1a-
SSD609-
3-
A0A0R4I951-
(U
niProt)-
2M
VT-
47-
C–C–C–CC–C-
KCN
E1/KCN
E3-
(209-nM
)--
HAN
D-toxin.-Indirectly-inhibits-KCN
Q
1-(K
V 7.1)-via-
interaction-w
ith-auxiliary-KCN
E1-or-KCN
E3-subunit.-
{Liu,-2012-
#11;Sun,-2015-#8}-
ρ"SLPTX
4 "Ssm
5b-
RhTx-
4-
A0A0N
7CSQ
4-
(U
niProt)-
2M
VA-
27-
C–C–C–C-
TRPV1-
(520-nM
)-
Agonist;-reduces-threshold-for-therm
al-activation-of-
TRPV1.-N
o-effect-on-TRPV2"4.-
{Yang,-2015-#9}-
Scolopin-Ssm
1a-
Scolopin-1-
*-
P0CH48-
(U
niProt)-
—
-
21-
N
o-cysteines-
Antim
icrobial-
Highly-effective-against-Staphylococcus,aureus.-
Has-m
oderate-hem
olytic-activity.-
{Peng,-2010-#99}-
Scolopin-Ssm
2a-
Scolopin-2-
*-
P0CH49-
(U
niProt)-
—
-
25-
N
o-cysteines-
Antim
icrobial-
Highly-effective-against-Staphylococcus,aureus.-
Has-m
oderate-hem
olytic-activity.-
{Peng,-2010-#99}-
Scolopin-Ssm
3a-
N
o-nam
e-given-
15
#-
N
ot-available-
—
-
12-
N
o-cysteines-
Antim
icrobial/-
cytotoxic-
Cytotoxic-to-hum
an-cancer-cell-lines;-w
eak-antim
icrobial-
activity;-anticoagulant-activity.-
{Kong,-2013-#100}-
